Eli Lilly & Company today announced plans to invest more than $1 billion in India over the next several years to expand contract manufacturing and increase patients' access to new medicines around the world. The strategic investment intends to improve Lilly's manufacturing and supply capabilities, thereby facilitating therapies for diabetes, Alzheimer's disease, cancer, obesity, and autoimmune disorders. 

As part of this plan, Lilly will open a new manufacturing & quality hub in Hyderabad, providing sophisticated technical capabilities and oversight for its contract manufacturing network throughout India. Contract manufacturing entails working with local companies to make pharmaceuticals, allowing Lilly to increase production more efficiently.

Engineers, chemists, analytical scientists, quality control and assurance professionals, and managerial positions will be available for hire immediately at the Hyderabad hub. Since 2020, Lilly has invested more than $55 billion globally to create and expand facilities, prepare for new medications, and improve patient access. 

Shri A. Revanth Reddy, Chief Minister of Telangana, stated that Lilly's continuous expansion in Hyderabad demonstrates the city's emergence as a worldwide healthcare innovation powerhouse. From the recent launch of its Innovation and Technology site to a new manufacturing collaboration and the establishment of a Manufacturing & Quality hub, Lilly is rapidly expanding its presence in Telangana, reinforcing the state's position as a preferred destination for cutting-edge healthcare investments." 

Shri Sridhar Babu, Telangana's Minister for IT, Industries & Commerce, and Legislative Affairs, said, "Lilly's expansion in Hyderabad demonstrates Telangana's dynamic industrial landscape and growing influence in advanced healthcare manufacturing." The state's emphasis on technology-driven infrastructure and ease of doing business continues to draw worldwide leaders across industries, with the life sciences industry in particular experiencing rapid growth." 

According to Nivruti Rai, MD & CEO, Invest India, Ministry of Commerce & Industry, Govt. of India, Lilly's investment in India reflects the country's growth as a manufacturing and innovation hub, as well as Lilly's commitment to global growth, innovation, and healthcare advancement. Together, we are building a stronger future for healthcare and manufacturing." 

Patrik Jonsson, Executive Vice President and President of Lilly International, stated that the company is investing heavily in global production and pharmaceutical supply capabilities to ensure patients have access to necessary medications. This investment reinforces our belief in India as a hub for capability development in our worldwide network." 

With established operations in Gurugram, Bengaluru, and Hyderabad, Lilly continues to benefit from India's skilled labour and robust infrastructure. The increased investment demonstrates the company's long-term commitment to the country and its mission to provide life-changing medications around the world.